Roland Liblau

Roland Liblau

Auto-generated profile, based on publicly available information

Roland Liblau

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University of Toulouse, CNRS, INSERM, UPS, 31024 Toulouse, France

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1995 in Immunology Today
Verified
Journal Article
Closed access
RLRoland S. Liblau
Roland S. Liblau
SSSteven Singer
Steven Singer
HMHugh O. McDevitt
Hugh O. McDevitt

19 July 2019 in Nature Reviews Neurology
Verified
Journal Article
Closed access
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
AAAntoine Adamantidis
Antoine Adamantidis
DBDenis Burdakov
Denis Burdakov
FHFang Han
Fang Han
SGSteffen Gay
Steffen Gay
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers

20 January 2018 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
XMXavier Montalban
Xavier Montalban
RGRalf Gold
Ralf Gold
ATAlan J Thompson
Alan J Thompson
SOSusana Otero-Romero
Susana Otero-Romero
MAMaria Pia Amato
Maria Pia Amato
FZFrauke Zipp
Frauke Zipp
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions. Objectives: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS. Methods: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients–Intervention–Comparator–Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique. Results: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus. Conclusion: The present guideline will enable homogeneity of treatment decisions across Europe.

4 June 2018 in Brain
Verified
Journal Article
Open access
PDF file
JMJoana Machado-Santos
Joana Machado-Santos
ESEtsuji Saji
Etsuji Saji
ATAnna Tröscher
Anna Tröscher
MPManuela Paunovic
Manuela Paunovic
RLRoland Liblau
Roland Liblau
HLHans Lassmann
Hans Lassmann
Multiple sclerosis is an inflammatory demyelinating disease in which active demyelination and neurodegeneration are associated with lymphocyte infiltrates in the brain. However, so far little is known regarding the phenotype and function of these infiltrating lymphocyte populations. In this study, we performed an in-depth phenotypic characterization of T and B cell infiltrates in a large set of multiple sclerosis cases with different disease and lesion stages and compared the findings with those seen in inflammatory, non-inflammatory and normal human controls. In multiple sclerosis lesions, we found a dominance of CD8+ T cells and a prominent contribution of CD20+ B cells in all disease courses and lesion stages, including acute multiple sclerosis cases with very short disease duration, while CD4+ T cells were sparse. A dominance of CD8+ T cells was also seen in other inflammatory controls, such as Rasmussen’s encephalitis and viral encephalitis, but the contribution of B cells in these diseases was modest. Phenotypic analysis of the CD8+ T cells suggested that part of the infiltrating cells in active lesions proliferate, show an activated cytotoxic phenotype and are in part destroyed by apoptosis. Further characterization of the remaining cells suggest that CD8+ T cells acquire features of tissue-resident memory cells, which may be focally reactivated in active lesions of acute, relapsing and progressive multiple sclerosis, while B cells, at least in part, gradually transform into plasma cells. The loss of surface molecules involved in the egress of leucocytes from inflamed tissue, such as S1P1 or CCR7, and the upregulation of CD103 expression may be responsible for the compartmentalization of the inflammatory response in established lesions. Similar phenotypic changes of tissue-infiltrating CD8+ T cells were also seen in Rasmussen’s encephalitis. Our data underline the potential importance of CD8+ T lymphocytes and B cells in the inflammatory response in established multiple sclerosis lesions. Tissue-resident T and B cells may represent guardians of previous inflammatory brain disease, which can be reactivated and sustain the inflammatory response, when they are re-exposed to their specific antigen.

25 August 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SFSylvain Fisson
Sylvain Fisson
GDGuillaume Darrasse-Jeze
Guillaume Darrasse-Jeze
ELElena Litvinova
Elena Litvinova
FSFranck Septier
Franck Septier
DKDavid Klatzmann
David Klatzmann
BSBenoît L. Salomon
Benoît L. Salomon
Despite a growing interest in CD4+ CD25+ regulatory T cells (Treg) that play a major role in self-tolerance and immunoregulation, fundamental parameters of the biology and homeostasis of these cells are poorly known. Here, we show that this population is composed of two Treg subsets that have distinct phenotypes and homeostasis in normal unmanipulated mice. In the steady state, some Treg remain quiescent and have a long lifespan, in the order of months, whereas the other Treg are dividing extensively and express multiple activation markers. After adoptive transfer, tissue-specific Treg rapidly divide and expand preferentially in lymph nodes draining their target self-antigens. These results reveal the existence of a cycling Treg subset composed of autoreactive Treg that are continuously activated by tissue self-antigens.

16 September 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NPNathalie Picard-Riera
Nathalie Picard-Riera
LDLaurence Decker
Laurence Decker
CDCécile DELARASSE
Cécile DELARASSE
KGKarine Goude
Karine Goude
BNBrahim Nait-Oumesmar
Brahim Nait-Oumesmar
AEAnne Baron-Van Evercooren
Anne Baron-Van Evercooren
The destiny of the mitotically active cells of the subventricular zone (SVZ) in adult rodents is to migrate to the olfactory bulb, where they contribute to the replacement of granular and periglomerular neurons. However, these adult neural progenitors also can be mobilized in periventricular white matter and triggered to differentiate into astrocytes and oligodendrocytes in response to lysolecithin-induced demyelination. To mimic the environmental conditions of multiple sclerosis, we assessed the proliferation, migration, and differentiation potential of adult SVZ progenitor cells in response to experimental autoimmune encephalomyelitis (EAE) in mice. Inflammation and demyelination were observed in all mouse brains after EAE induction. EAE induced cell proliferation throughout the brain and especially within the lesions. Proliferating cells were neural progenitors, astrocytes, and oligodendrocyte precursors. EAE enhanced the migration of SVZ-derived neural progenitors to the olfactory bulb and triggered their mobilization in the periventricular white matter. The mobilized cells gave rise to neurons, astrocytes, and oligodendrocytes in the olfactory bulb but essentially to astrocytes and oligodendrocytes in the lesioned white matter. Our data indicate that the adult mouse SVZ is a source of newly generated oligodendrocytes and thus may contribute, along with oligodendrocyte precursors, to the replacement of oligodendrocytes in inflammatory demyelinating diseases of the central nervous system such as multiple sclerosis.